We are live on ! Find out more
Seven Grand Managers

Seven Grand Managers Portfolio holdings

AUM $2.74B Turnover 54.42%
1-Year Est. Return 33.82%
This Fund
S&P 500
This Quarter Est. Return
-5.51%
1 Year Est. Return
+33.82%
3 Year Est. Return
+283.18%
5 Year Est. Return
+317.15%
10 Year Est. Return
–
AUM
$2.74B
AUM Growth
+$254M
Cap. Flow
+$117M
Cap. Flow %
4.28%
Top 10 Hldgs %
57.42%
Holding
226
New
50
Increased
13
Reduced
25
Closed
73
Avg Time Held Equity + Options
0.3 years
Top 10 Avg Time Held Equity + Options
0.2 years
Top 20 Avg Time Held Equity + Options
0.2 years
Avg Time Held Equity only
0.4 years
Top 10 Avg Time Held Equity only
0.2 years
Top 20 Avg Time Held Equity only
0.3 years

Top Buys

Rank Stock Value
1
INTC icon
Intel
INTC
+$204M
2
SKHY icon
SK Hynix
SKHY
+$165M
3
CLS icon
Celestica
CLS
+$165M
4
RIVN icon
Rivian
RIVN
+$64.9M
5
AAPL icon
Apple
AAPL
+$64.6M

Top Sells

Rank Stock Value
1
DLR icon
Digital Realty Trust
DLR
+$103M
2
NVDA icon
NVIDIA
NVDA
+$80.7M
3
AEP icon
American Electric Power
AEP
+$54.7M
4
FANG icon
Diamondback Energy
FANG
+$52.7M
5
ETR icon
Entergy
ETR
+$45.9M

Sector Composition

Rank Sector Weight
1 Technology 31.49%
2 Industrials 21.21%
3 Healthcare 14.13%
4 Miscellaneous 11.25%
5 Consumer Discretionary 6.91%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
AXON icon
101
Axon Enterprise
AXON
$23.7B
$2.59M 0.09%
+6,134
New +$3.31M
2026 Q3
0 quarters
AVR icon
102
Anteris Technologies
AVR
$486M
$2.53M 0.09%
325,000
+300,000
+1,200% +$2.6M
2026 Q1
2 quarters
FCEL icon
103
FuelCell Energy
FCEL
$535M
$2.46M 0.09%
+150,000
New +$2.95M
2026 Q3
0 quarters
TSHA icon
104
Taysha Gene Therapies
TSHA
$1.21B
$2.44M 0.09%
+500,000
New +$2.88M
2026 Q3
0 quarters
NHP icon
105
National Healthcare Properties
NHP
$1.08B
$2.41M 0.09%
150,000
-50,000
-25% -$800K
2026 Q2
1 quarter
RDVT icon
106
Red Violet
RDVT
$1.09B
$2.37M 0.09%
+30,000
New +$2.12M
2026 Q3
0 quarters
LFTO icon
107
Liftoff Mobile
LFTO
$3.87B
$2.37M 0.09%
150,000
– –
2026 Q2
1 quarter
EROK icon
108
EagleRock Land
EROK
$519M
$2.34M 0.09%
112,500
-37,500
-25% -$871K
2026 Q2
1 quarter
IRON icon
109
Disc Medicine
IRON
$3.42B
$2.29M 0.08%
35,000
– –
2025 Q4
3 quarters
BRVE
110
Braveheart Bio
BRVE
$1.84B
$2.27M 0.08%
+112,500
New +$2.96M
2026 Q3
0 quarters
AVEX icon
111
AEVEX
AVEX
$764M
$2.27M 0.08%
150,000
-150,000
-50% -$2.6M
2026 Q2
1 quarter
YSWY icon
112
Yesway
YSWY
$627M
$2.27M 0.08%
112,500
-37,500
-25% -$820K
2026 Q2
1 quarter
AGMB icon
113
AgomAb Therapeutics
AGMB
$268M
$2.22M 0.08%
200,000
+152,400
+320% +$1.97M
2026 Q1
2 quarters
TRVI icon
114
Trevi Therapeutics
TRVI
$1.9B
$2.15M 0.08%
150,000
– –
2026 Q2
1 quarter
AVLN icon
115
Avalyn Pharma
AVLN
$1.26B
$2.14M 0.08%
75,000
– –
2026 Q2
1 quarter
HGTY icon
116
Hagerty
HGTY
$2.13B
$2.02M 0.07%
+150,000
New +$1.93M
2026 Q3
0 quarters
LIFE icon
117
Ethos Technologies
LIFE
$2.03B
$2.01M 0.07%
60,000
– –
2026 Q1
2 quarters
JSPR icon
118
Jasper Therapeutics
JSPR
$9.6M
$2M 0.07%
+2,351
New +$47.4K
2026 Q3
0 quarters
KLRA icon
119
Kailera Therapeutics
KLRA
$1.43B
$2M 0.07%
175,000
– –
2026 Q2
1 quarter
BLLN icon
120
BillionToOne
BLLN
$4.3B
$1.96M 0.07%
18,437
-6,563
-26% -$736K
2025 Q4
3 quarters
IDYA icon
121
IDEAYA Biosciences
IDYA
$2.47B
$1.92M 0.07%
50,000
– –
2026 Q2
1 quarter
GENB icon
122
Generate Biomedicines
GENB
$1.23B
$1.88M 0.07%
125,000
– –
2026 Q1
2 quarters
WHK icon
123
WhiteHawk Minerals
WHK
$637M
$1.84M 0.07%
75,000
-25,000
-25% -$665K
2026 Q2
1 quarter
JAZZ icon
124
Jazz Pharmaceuticals
JAZZ
$14.8B
$1.63M 0.06%
+7,038
New +$1.74M
2026 Q3
0 quarters
CLDX icon
125
Celldex Therapeutics
CLDX
$2.15B
$1.62M 0.06%
50,000
– –
2026 Q2
1 quarter

Similar funds

Seven Grand Managers's Q3 2026 Portfolio in Review

As of Q3 2026, Seven Grand Managers held 226 positions worth $2.74B, up 10% from $2.48B the previous quarter. Its ten largest holdings account for 57% of the portfolio.

Seven Grand Managers deployed $117M of net new capital in Q3 2026, opening 50 new positions and adding to 13 existing holdings. Its largest new stake was Intel: 2,000,000 shares worth $240M.

By sector, the portfolio is most concentrated in Technology at 31% of assets, up from 12% a quarter earlier, followed by Industrials and Healthcare.

On the sell side, the largest reduction was NVIDIA, an estimated $80.7M trimmed.

  • Seven Grand Managers's largest Q3 2026 buy was Intel: 2,000,000 shares worth $240M.
  • Seven Grand Managers added most to Microsoft in Q3 2026, an estimated $47.6M increase.
  • Seven Grand Managers's biggest Q3 2026 reduction was NVIDIA, cutting an estimated $80.7M.
  • Seven Grand Managers fully exited Digital Realty Trust in Q3 2026, selling an estimated $103M.
  • Seven Grand Managers's ten largest holdings make up 57% of its $2.74B portfolio in Q3 2026.
  • Seven Grand Managers opened 50 new positions and closed 73 in Q3 2026.
  • Seven Grand Managers's portfolio value rose 10% quarter-over-quarter to $2.74B.

Based on Seven Grand Managers's 13F filing for Q3 2026, filed 16 Nov 2026.